Related Experiment Video

Updated: Jun 19, 2026

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy
08:51

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

IDH1-R132H enhances oncolytic HSV-1 therapy by facilitating viral entry and immune activation in glioma

Eleni Panagioti1,2, Hunter J Kelley3, Alexander L Ling3

  • 1Harvey Cushing Neuro-oncology Laboratories, Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. epanagio@bidmc.harvard.edu.

Nature Communications
|June 17, 2026
PubMed

Insights

This study shows that the IDH1-R132H mutation in gliomas makes them more sensitive to oncolytic virus therapy (CAN-3110). Combining this therapy with TIGIT blockade improves treatment outcomes for these difficult-to-treat brain tumors.

Area of Science:

  • Oncology
  • Virology
  • Immunology

Background:

  • High-grade astrocytomas with IDH mutations have poor prognoses.
  • Oncolytic virotherapy offers a potential precision treatment strategy.
  • Targeting tumor-specific molecular profiles is key for effective cancer therapy.

Purpose of the Study:

  • To evaluate the efficacy of rQNestin34.5v.2 (CAN-3110), an oncolytic herpes simplex virus 1 (oHSV-1), in IDH1-R132H-mutant diffuse gliomas.
  • To understand how the IDH1-R132H mutation influences glioma response to oHSV-1.
  • To explore combination strategies to overcome potential resistance mechanisms.

Main Methods:

  • Investigated viral susceptibility in IDH1-R132H-mutant gliomas.
  • Assessed the impact of IDH1-R132H on interferon signaling and viral replication.
  • Utilized immunocompetent murine glioma models for in vivo efficacy studies.
  • Analyzed immune activation, infiltration, and expression of immune checkpoints like TIGIT.

Main Results:

  • The IDH1-R132H mutation increases glioma susceptibility to CAN-3110 via Nectin-1 upregulation.
  • IDH1-R132H-driven hypermethylation suppresses interferon signaling, promoting viral replication and apoptosis.
  • Intratumoral CAN-3110 induced antitumor immunity in murine models.
  • Elevated PVR and TIGIT suggest potential resistance to virotherapy.

Conclusions:

  • IDH1-R132H mutation creates a permissive microenvironment for oncolytic virotherapy.
  • Combination of CAN-3110 with TIGIT blockade enhances therapeutic efficacy.
  • IDH1-R132H may serve as a predictive biomarker for oncolytic virotherapy response.

More Related Videos

Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus06:14

Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus

Published on: May 13, 2021

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cytomegalovirus Disease01:27

Cytomegalovirus Disease

Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...